Nora Adriana Hernández  Cuevas

Dr. Nora Adriana Hernández Cuevas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Parasitology
Verified
Journal Article
Closed access
PDF file
NCNora Adriana Hernández Cuevas
Nora Adriana Hernández Cuevas
AMAndrea Marín-Cervera
Andrea Marín-Cervera
SGShineily Garcia-Polanco
Shineily Garcia-Polanco
PMPedro Martínez-Vega
Pedro Martínez-Vega
MRMiguel Rosado-Vallado
Miguel Rosado-Vallado
EDEric Dumonteil
Eric Dumonteil
Biomarkers (coming from host or parasite) to monitor Chagas disease (CD) progression as well as the therapeutic response in chronic CD are critically needed, since seronegativization, which may be considered the best indicator of therapeutic cure, takes several years to be observed in adults. Several molecules have been suggested as biomarkers for CD, however, they have to be validated. Taking advantage of mouse models of Trypanosoma cruzi infection, we investigated changes in the degradation profile of fibronectin in plasma. The degradation profile of fibronectin was different in the acute phase compared to the chronic phase of the infection. Fibronectin fragments of approximately 150, 100, 40 and 30 kDa were identified. Furthermore, those degradation profiles correlated with acute parasitaemia as well as with cardiac parasite burden and tissue damage during the infection. The usefulness of fibronectin degradation as a biomarker for therapeutic response following drug treatment and immunotherapeutic vaccination also was evaluated and a decreased fibronectin degradation profile was observed upon benznidazole or a vaccine candidate treatment.

26 August 2025 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
LUIS PABLO LOPEZ LOPEZLUIS PABLO LOPEZ LOPEZ
LUIS PABLO LOPEZ LOPEZ
NCNora Adriana Hernández Cuevas
Nora Adriana Hernández Cuevas
Karla Y. Acosta-VianaKarla Y. Acosta-Viana
Karla Y. Acosta-Viana
Victor Ermilo Arana ArgaezVictor Ermilo Arana Argaez
Victor Ermilo Arana Argaez
JTJulio Cesar Torres-Romero
Julio Cesar Torres-Romero
GHGlendy M. Polanco Hernández
Glendy M. Polanco Hernández
Trypanosoma cruzi is the protozoan parasite that causes Chagas disease, affecting approximately 6–7 million people worldwide. The current treatment lacks efficacy in the chronic phase of the disease. This study aims to determine the in vitro synergistic activity of concomitant therapy (benznidazole with β-caryophyllene oxide) against Trypanosoma cruzi, assess its cytotoxicity, and propose the mechanism of this synergism through in silico analysis. The tested concentrations of the treatment demonstrated hemocompatibility (80% cell viability). Additionally, synergistic activity against the parasite was confirmed, reducing epimastigote viability by up to 80%. In this work, in silico analysis revealed that β-caryophyllene oxide also binds to the T. cruzi ABC channel in regions localized to amino acids 108–271 and 399–558, suggesting this interaction could inhibit it. This treatment emerges as a promising candidate for Chagas disease therapy. It lacks cytotoxic and hemolytic activity while exhibiting synergism against the parasite, such as through the inhibition of ABC channels, as suggested in silico.